CEPI gave 388 millions to NVAX based on its NVX-CoV2373 pre-clinical data, which is largest investment CEPI has done so far.
NVX-CoV2373 will be the best in class for covid-19 vaccines when its phase I immunological data becoming available in later July to compare to any other front runner covid-19 phase I data
Novavax Announces Positive Top-Line Data From Phase 1 Ebola Vaccine Trial on WHO Teleconference
GAITHERSBURG, Md., July 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the
discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced positive top-line data from a
Phase 1 clinical trial of its Ebola virus glycoprotein (GP) recombinant
nanoparticle vaccine candidate adjuvanted with Matrix-M™ as part of the
World Health Organization’s (WHO) Fifth Teleconference on Ebola Vaccine
Clinical Trials. The trial demonstrated that the Ebola GP Vaccine was
highly immunogenic, well-tolerated and, in conjunction with Novavax’
proprietary Matrix-M adjuvant, resulted in significant antigen
The Ebola GP Vaccine clinical trial is a randomized,
observer-blinded, dose-escalation trial to evaluate the safety and
immunogenicity of the vaccine, with and without Matrix-M, in 230 healthy
adults between 18 and 49 years of age. Participants received either one
or two intramuscular injections ranging from 6.5µg to 50µg of antigen
on study days 0 and 21. Immunogenicity was assessed at multiple time
points including days 28 and 35.
The adjuvanted Ebola GP Vaccine was highly
immunogenic at all dose levels. The adjuvanted two-dose regimens induced
Ebola anti-GP antibody geometric mean responses between 45,000 and
70,000 ELISA units (GMEU), representing a 500 to 750-fold rise over
baseline at day 35. The adjuvanted single dose vaccine regimen induced
GMEU between 1700 and 3400, representing a 21 to 27-fold rise over
baseline at day 35.